Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrodysplasia Ossificans Progressiva (FOP) and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACVR1/ALK-2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ACVR1 ECD-Fc / Kinase Domain Protein (WT). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. | View ACVR1 Products |
| Mutant Antigen | ACVR1 R206H (FOP Mutant) Recombinant Protein. Pathogenic variant for selective inhibitor screening. Additional mutants Q207D, R258S, G356D available. Sequence Verified. HEK293 expressed with native glycosylation. | View ACVR1 Products |
| Gene Delivery | ACVR1 Lentivirus Particles. Full-length ORF for stable cell line construction in Ba/F3 or HEK293. CMV promoter. | View ACVR1 Products |
| Benchmark Ab | Anti-ACVR1 Reference Antibody (Neutralizing / Clinical Benchmark Sequence). Recombinant positive control for ligand competition assays and assay calibration. | View ACVR1 Products |
| Validator | ACVR1 siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View ACVR1 Products |
| Related Target: Activin A | Ligand that drives mutant ACVR1 signaling in FOP. Essential for ligand binding studies. | View Activin A Products |
| Type II Receptor Partner | ACVR2A (Activin Receptor Type 2A). Forms signaling complex with ACVR1; essential for BMP ligand binding assays. | View ACVR2A Products |
| Alternative Type II Receptor | BMPR2 (BMP Receptor Type 2). Alternative complex partner; critical for cross-reactivity profiling. | View BMPR2 Products |
| Downstream Effector | SMAD1 Recombinant Protein. Signal transducer validation; phosphorylation substrate for kinase assays and cellular signaling readout. | View SMAD1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ALK1/ALK3/ALK4/ALK5 Selectivity Screening | Homolog Panel Available: ACVR1, ACVRL1 (ALK1), BMPR1A (ALK3), ACVR1B (ALK4), TGFBR1 (ALK5) ECD proteins strictly verified by mass spec (>95% purity) for cross-binding assays. |
| FOP Mutant vs WT Discrimination | R206H, Q207D, R258S, G356D pathogenic mutants expressed in HEK293 with native glycosylation for selectivity profiling. Wild-type protein also available. |
| Ligand Binding Specificity (BMP2/4/6/7 vs Activin A) | High-purity ECD-Fc with confirmed conformational folding (theoretical MW verified) for SPR/BLI studies. |
| Cell Signaling Validation & Control | Lentivirus for stable cell line generation preserving native membrane conformation; ideal for SMAD1/5/8 phosphorylation assays. Includes clinical benchmark antibodies for assay calibration and sequence-verified siRNA for specificity control. |
| Cross-species Preclinical Translation | Human/Mouse/Cyno ortholog proteins available with sequence-verified extracellular domains. |
Live ACVR1/ALK-2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ACVR1/ALK-2 therapeutics is intensifying, with major players shifting focus from systemic bone modification to highly selective targeted inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific genetic drivers of Fibrodysplasia Ossificans Progressiva (FOP) and pediatric brain tumors like Diffuse Intrinsic Pontine Glioma (DIPG), as well as combination regimens for acute myeloid leukemia (AML). Following recent clinical setbacks with non-selective inhibitors, the primary challenge lies in achieving profound selectivity for the mutant ACVR1 (predominantly R206H) over wild-type to mitigate off-target skeletal, hematological, and cardiovascular toxicities. CNS penetrancy is a critical differentiator for DIPG indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Kinase Inhibitors | Ipsen, Blueprint Medicines, Incyte, Keros Therapeutics, BioCryst, Novartis | FOP, DIPG, AML, Anemia | Selectivity Assay (Need High-Purity Mutant vs WT Proteins and ALK homologous panel) |
| Monoclonal Antibodies (Targeting Ligand/Receptor) | Regeneron, Regenerative Medicine, Early Phase Biotechs | FOP, Oncology | Binding/Blocking Assays (Need HEK293 Expressed ECD-Fc for ligand trap or full-length ACVR1 lentivirus cells for internalization) |
| ECD-Fc Decoy (Ligand Trap) | Preclinical Biotechs | FOP (Prevention) | Ligand Binding Affinity (Need high-purity ECD-Fc with native glycosylation for BMP2/4/7 binding kinetics) |
| Gene Therapy / RNAi | Academic/Biotech Consortiums | FOP, DIPG, Genetic Disorders | Expression Validation Controls (Need wild-type vs mutant protein standards and siRNA for specificity) |